Latigo Biotherapeutics, Inc. (LTGO)
12.50
-0.51
(-3.92%)
USD |
NASDAQ |
Nov 06, 10:20
Latigo Biotherapeutics Enterprise Value : 1.127B for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 1.127B |
| November 04, 2026 | 1.195B |
| November 03, 2026 | 1.231B |
| November 02, 2026 | 1.160B |
| October 30, 2026 | 1.190B |
| October 29, 2026 | 1.295B |
| October 28, 2026 | 1.314B |
| October 27, 2026 | 1.273B |
| October 26, 2026 | 1.276B |
| October 23, 2026 | 1.260B |
| October 22, 2026 | 1.363B |
| October 21, 2026 | 1.348B |
| October 20, 2026 | 1.276B |
| October 19, 2026 | 1.213B |
| October 16, 2026 | 1.193B |
| October 15, 2026 | 1.243B |
| October 14, 2026 | 1.193B |
| October 13, 2026 | 1.306B |
| October 12, 2026 | 1.327B |
| October 09, 2026 | 1.325B |
| October 08, 2026 | 1.245B |
| October 07, 2026 | 1.294B |
| October 06, 2026 | 1.343B |
| October 05, 2026 | 1.367B |
| October 02, 2026 | 1.319B |
| Date | Value |
|---|---|
| October 01, 2026 | 1.371B |
| September 30, 2026 | 1.372B |
| September 29, 2026 | 1.465B |
| September 28, 2026 | 1.424B |
| September 25, 2026 | 1.402B |
| September 24, 2026 | 1.442B |
| September 23, 2026 | 1.589B |
| September 22, 2026 | 1.645B |
| September 21, 2026 | 1.664B |
| September 18, 2026 | 1.760B |
| September 17, 2026 | 1.851B |
| September 16, 2026 | 1.793B |
| September 15, 2026 | 1.790B |
| September 14, 2026 | 1.766B |
| September 11, 2026 | 1.733B |
| September 10, 2026 | 1.693B |
| September 09, 2026 | 1.776B |
| September 08, 2026 | 1.838B |
| September 04, 2026 | 1.792B |
| September 03, 2026 | 1.755B |
| September 02, 2026 | 1.708B |
| September 01, 2026 | 1.740B |
| August 31, 2026 | 1.725B |
| August 28, 2026 | 1.871B |
| August 27, 2026 | 1.922B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Turn Therapeutics, Inc. | 262.14M |
| Journey Medical Corp. | 118.82M |
| ANI Pharmaceuticals, Inc. | 1.834B |
| Corcept Therapeutics, Inc. | 7.472B |
| Veru, Inc. | 12.02M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.80M |
| Total Expenses (Quarterly) | 25.80M |
| EPS Diluted (Quarterly) | -0.3891 |
| Earnings Yield | -11.94% |
| Normalized Earnings Yield | -11.86 |